Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Bladder Medley
NCT05327530Phase 2Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of avelumab in urothelial carcinoma (UC) (5 arms), sponsored by EMD Serono. Primary endpoints: Progression-Free Survival up to 41 months and Treatment Emergent Adverse Events. Started Aug 2022; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05327530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327530.